Traditional Chinese medicine composition for treating hyperuricemia and gout as well as preparation method and application of traditional Chinese medicine composition
Through traditional Chinese medicine compositions such as Scutellaria baicalensis, Coptis chinensis, Chainus, Forsythia, White Peony and other traditional Chinese medicine compositions, the safety and long-term use of existing gout treatment drugs have been solved, and effective reduction of blood uric acid and alleviated gout joints have been achieved. The effect of inflammation has excellent therapeutic effect and low cost characteristics.
Patent Information
- Application Number
- CN202411101051.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-12
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-08-12
AI Technical Summary
Existing gout treatment drugs have renal impairment, cardiovascular risk, hyponatremia, hypokalemia, hypocalcemia and unsuitable for long-term use, which is difficult to effectively reduce blood uric acid levels and alleviate gout arthritis.
Using traditional Chinese medicine compositions such as Scutellaria baicalensis, Coptis chinensis, Chainus, Forsythia, and White Peony, it is used to prepare traditional Chinese medicine compositions for reducing blood by clearing heat and drying dampness, detoxifying, relieving liver and regulating qi, nourishing blood, etc. Uric acid levels and relieve gouty arthritis.
This traditional Chinese medicine composition is safe and has no adverse reactions for long-term use. Its efficacy is better than that of commonly used Western medicines in clinical practice. It effectively reduces blood uric acid, relieves gouty arthritis, and has good analgesic effects, is low in cost and is simple in preparation.
Smart Images

Figure CN118903285A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of traditional Chinese medicine, and in particular to a traditional Chinese medicine composition for treating hyperuricemia and gout, a preparation method of the traditional Chinese medicine composition for treating hyperuricemia and gout, and application of the traditional Chinese medicine composition in treating hyperuricemia and gout. Background Art
[0002] Gout is a metabolic disease associated with purine metabolism disorders or uric acid excretion disorders. The incidence rate in China is 1.1%. Characteristic manifestations include hyperuricemia, redness, swelling, heat and pain in the joints, and deposition of urate crystals in the joints. Recurrent attacks of the disease may cause tophi and deformities of the affected joints.
[0003] Hyperuricemia is a metabolic disease with a worldwide incidence of 5%-25%, and the incidence in China is also over 10%. With the improvement of living standards, the intake of high calories, high fat, and high protein has increased, and the incidence of hyperuricemia has gradually increased, and it has shown a trend of younger people. The disease recurs repeatedly, seriously endangering human health.
[0004] Uric acid is a normal metabolite of the body. The uric acid level in serum is 149-416μΜ for men and 89-357μΜ for women. The clinical diagnostic criteria for hyperuricemia are: fasting serum uric acid level>416.0μΜ for men and>356.9μΜ for women. Hyperuricemia can cause gout and kidney damage, and is an important risk factor for diabetes, hypertension, and cardiovascular disease. When serum uric acid in the body is higher than 6.0mg / dL for a long time, sodium urate crystals may be deposited in joints, soft tissues and other parts, thereby inducing acute arthritis and becoming a key factor in causing gout. If patients with hyperuricemia are not treated, about 12% of patients may develop tophi after 5 years, and the probability of developing tophi after 20 years is 55%.
[0005] Lowering blood uric acid levels and treating acute gouty arthritis are two strategies for preventing and treating gout. Among them, lowering blood uric acid is a treatment for the cause of gout and has become an effective means of treating gout. Currently, drugs that lower uric acid include: ① xanthine oxidase inhibitors allopurinol and febuxostat that inhibit uric acid production; ② probenecid and benzbromarone that promote uric acid excretion. Commonly used drugs for acute gouty arthritis include: non-steroidal anti-inflammatory drugs, colchicine, glucocorticoids and analgesics. Allopurinol and febuxostat are restricted in use due to renal impairment or cardiovascular death risk; uricosuric drugs such as benzbromarone can cause hyponatremia, hypokalemia, hypocalcemia, and damage to the liver and kidneys, and are not suitable for long-term use; non-steroidal drugs, colchicine, and glucocorticoids for acute gouty arthritis are also not suitable for long-term use. Therefore, it is urgent to develop safe and effective drugs that can reduce uric acid and relieve gouty arthritis that are suitable for long-term use. Summary of the invention
[0006] In order to overcome the defects of the prior art, the technical problem to be solved by the present invention is to provide a traditional Chinese medicine composition for treating hyperuricemia and gout, which can effectively reduce blood uric acid levels, relieve gouty arthritis, and has a good analgesic effect. The efficacy is better than that of commonly used Western medicines in clinical practice. The raw materials used are low in price and the preparation process is simple, which greatly reduces the cost of medicines.
[0007] The technical solution of the present invention is: the traditional Chinese medicine composition for treating hyperuricemia and gout is prepared from the following raw materials in parts by weight: 3-12 parts by weight of scutellaria baicalensis, 1.5-6 parts by weight of coptis chinensis, 1.5-6 parts by weight of phellodendron chinense, 2-8 parts by weight of gardenia jasmine, 3-12 parts by weight of bupleurum, 2-8 parts by weight of forsythia suspensa, and 2-8 parts by weight of white peony root.
[0008] The Chinese medicine composition of the present invention can reduce hyperuricemia and relieve gout, the raw materials used are highly safe, long-term use will not produce adverse reactions, effectively reduce blood uric acid levels, relieve gouty arthritis, and has a good analgesic effect, and the therapeutic effect is better than that of commonly used Western medicines in clinical practice. The Chinese medicine composition of the present invention is prepared as a preparation using a conventional preparation method, the raw materials used are low in price, the preparation process is simple, and the cost of the medicine is greatly reduced.
[0009] Also provided is a method for preparing the Chinese medicine composition for treating hyperuricemia and gout. The Chinese medicine composition is prepared by mixing the raw materials after crushing, or is an extract obtained by mixing or extracting the raw materials separately, or is an effective part obtained by further refining and purifying the extract, or is a conventional dosage form prepared by adding pharmaceutically acceptable excipients to the extract / effective part.
[0010] Also provided is the use of a traditional Chinese medicine composition for treating hyperuricemia and gout in preparing a medicine for treating hyperuricemia and / or gout. BRIEF DESCRIPTION OF THE DRAWINGS
[0011] Figure 1 19 are the pathological test results of mice in each group (×100), wherein AH are the pathological images of normal control group, model group, prescription group 1, prescription group 2, prescription group 3, febuxostat group, benzbromarone group, and Tongfengshu tablets group, respectively. DETAILED DESCRIPTION
[0012] Pharmacological studies have shown that the Chinese medicine composition of the present invention can effectively reduce blood uric acid levels, relieve gouty arthritis, and has a good analgesic effect, and its therapeutic effect is better than that of commonly used Western medicines in clinical practice.
[0013] In view of the pathogenesis of gouty arthritis, the present invention has screened a variety of drugs in the early stage, for example, drugs with the effects of clearing away heat and drying dampness, such as Scutellaria baicalensis, Coptis chinensis, Phellodendron chinense, and Sophora flavescens; drugs with the effects of clearing heat and detoxifying, such as Honeysuckle, Forsythia suspensa, Trillium gracile, and Gardenia jasminoides; drugs with the effects of soothing the liver and regulating qi, such as Bupleurum chinense and Cyperus rotundus; drugs with the effects of nourishing blood and activating blood circulation, such as White Peony Root, Angelica sinensis, Chuanxiong, and Salvia miltiorrhiza; drugs with the effects of promoting diuresis and eliminating dampness, such as Poria cocos, Coix seed, Alisma orientalis, and Artemisia capillaris.
[0014] Through screening, the Chinese medicine composition of the specific compatibility of the present invention is finally obtained, namely, scutellaria, coptis, phellodendron, stir-fried gardenia, bupleurum, forsythia, white peony root. Forsythia is the monarch in the prescription, clearing away heat and detoxicating, eliminating carbuncle and dispersing knots. It can enter the blood and "transmit heat and transform qi" to treat the damp heat of the blood for a long time. It can also go through the meridians, joints, skin, flesh and tendons, dissolve the condensed turbid toxins to relieve numbness and relieve pain, and is most suitable for treating local redness, swelling, heat and pain in the joints, especially at night, so it is the monarch drug; scutellaria, coptis, phellodendron, gardenia purge the fire poison of the triple energizer, bitter cold and direct heat, and are all minister drugs; and it is assisted by bitter, pungent and slightly cold bupleurum and bitter, sour and slightly cold white peony root, soothing the liver and softening the tendons, relieving pain, and assisting in the treatment of pain and poor activity of gouty arthritis. The compatibility of all the medicines has the merits of clearing heat, drying dampness and detoxicating, and reducing swelling and relieving pain. It is used for damp-heat turbidity, blocking joints, and local redness, swelling, heat, and pain in joints caused by excessive heat in the triple energizer, accompanied by irritability, red face and eyes, dry mouth and throat, sweating, bad breath, red and astringent urine, red tongue, yellow or greasy coating, and stringy and slippery or stringy and rapid pulse. It is also used for patients with the above symptoms during the acute attack of hyperuricemia and gouty arthritis.
[0015] The combination of Bupleurum and White Peony has the following two effects: First, both enter the liver meridian, and the combination of the two medicines nourishes liver blood, restrains liver yin, relieves liver depression, and regulates liver qi, which is in line with the physiological characteristics of the liver "body yin uses yang"; and the liver governs tendons, and the knee is the combination of tendons. If the tendons are soft, the limbs can move freely. Therefore, Bupleurum and White Peony can relieve liver and soften tendons, relieve pain, and assist in the treatment of pain and poor mobility of gouty arthritis. Second, the whole prescription uses mostly bitter and cold drugs, which hinder the ascending qi of Shaoyang and are not conducive to the circulation of qi and blood. Bupleurum and White Peony are both slightly cold products, which can not only raise the qi of the liver and gallbladder to regulate qi and blood, but also have no risk of the pungent and warm products that help blood boil, and have the function of counter-assistance, which is the compatibility feature of the present invention.
[0016] The Chinese medicine composition for treating hyperuricemia and gout is prepared from the following raw materials in parts by weight: 3-12 parts by weight of scutellaria baicalensis, 1.5-6 parts by weight of coptis chinensis, 1.5-6 parts by weight of phellodendron chinense, 2-8 parts by weight of gardenia jasmine, 3-12 parts by weight of bupleurum, 2-8 parts by weight of forsythia suspensa, and 2-8 parts by weight of white peony root.
[0017] The Chinese medicine composition of the present invention can reduce hyperuricemia and relieve gout, the raw materials used are highly safe, long-term use will not produce adverse reactions, effectively reduce blood uric acid levels, relieve gouty arthritis, and has a good analgesic effect, and the therapeutic effect is better than that of commonly used Western medicines in clinical practice. The Chinese medicine composition of the present invention is prepared as a preparation using a conventional preparation method, the raw materials used are low in price, the preparation process is simple, and the cost of the medicine is greatly reduced.
[0018] Preferably, the traditional Chinese medicine composition is made of the following raw materials in parts by weight: 4-8 parts by weight of Scutellaria baicalensis, 2-4 parts by weight of Coptidis chinensis, 2-4 parts by weight of Phellodendron chinense, 3-6 parts by weight of Gardenia jasminoides, 4-8 parts by weight of Bupleurum chinense, 3-6 parts by weight of Forsythia suspensa, and 3-6 parts by weight of White Peony Root.
[0019] Preferably, the traditional Chinese medicine composition is made of the following raw materials in parts by weight: 6 parts by weight of Scutellaria baicalensis, 3 parts by weight of Coptidis chinensis, 3 parts by weight of Phellodendron chinense, 4 parts by weight of Gardenia jasminoides, 6 parts by weight of Bupleurum chinense, 4 parts by weight of Forsythia suspensa, and 4 parts by weight of White Peony Root.
[0020] Alternatively, the Chinese medicine composition is made of the following raw materials in parts by weight: 5 parts by weight of Scutellaria baicalensis, 3.5 parts by weight of Coptidis chinensis, 2.5 parts by weight of Phellodendron chinense, 5.5 parts by weight of Gardenia jasminoides, 4.5 parts by weight of Bupleurum chinense, 5.5 parts by weight of Forsythia suspensa, and 3.5 parts by weight of White Peony Root.
[0021] Alternatively, 7 parts by weight of Scutellaria baicalensis, 2.5 parts by weight of Coptidis chinensis, 3.5 parts by weight of Phellodendron chinense, 3 parts by weight of Gardenia jasminoides, 7 parts by weight of Bupleurum chinense, 3 parts by weight of Forsythia suspensa, and 5 parts by weight of White Peony Root.
[0022] Preferably, the gardenia is fried gardenia.
[0023] Also provided is a method for preparing the Chinese medicine composition for treating hyperuricemia and gout. The Chinese medicine composition is prepared by mixing the raw materials after crushing, or is an extract obtained by mixing or extracting the raw materials separately, or is an effective part obtained by further refining and purifying the extract, or is a conventional dosage form prepared by adding pharmaceutically acceptable excipients to the extract / effective part.
[0024] Preferably, the extraction includes: decoction extraction, reflux extraction, immersion extraction, ultrasonic extraction, percolation extraction, microwave extraction; the purification includes: water extraction and alcohol precipitation, alkali dissolution and acid precipitation, various column chromatography purification methods; the conventional dosage forms include: capsules, tablets, granules, gels, sustained-release preparations, oral liquids, pills or nanoformulations; the pharmaceutically acceptable excipients include: fillers, disintegrants, lubricants, suspending agents, adhesives, sweeteners, flavoring agents, preservatives, and bases; the fillers include: starch, pregelatinized starch, emulsifiers, Sugar, mannitol, chitin, microcrystalline cellulose, sucrose; the disintegrant includes: starch, pregelatinized starch, microcrystalline cellulose, sodium carboxymethyl starch, cross-linked polyvinyl pyrrolidone, low-substituted hydroxypropyl cellulose, cross-linked sodium carboxymethyl cellulose; the lubricant includes: magnesium stearate, sodium lauryl sulfate, talc, silicon dioxide; the suspending agent includes: polyvinyl pyrrolidone, microcrystalline cellulose, sucrose, agar, hydroxypropyl methylcellulose; the binder includes: starch slurry, polyvinyl pyrrolidone, hydroxypropyl methylcellulose.
[0025] Preferably, the extract is a water extract of each raw material drug, or an organic solvent extract, or a refined product obtained by further refining and purification of the water extract / organic solvent extract; the organic solvent is selected from one or more of methanol, 20-95% ethanol solution, and acetone.
[0026] Also provided is the use of a traditional Chinese medicine composition for treating hyperuricemia and gout in preparing a medicine for treating hyperuricemia and / or gout.
[0027] The embodiments of the present invention are described in detail below.
[0028] Example 1
[0029] Prescription: Scutellaria baicalensis 6g, Coptis chinensis 3g, Phellodendron amurense 3g, stir-fried Gardenia jasminoides 4g, Bupleurum chinense 6g, Forsythia suspensa 4g, White Peony Root 4g;
[0030] The raw materials are taken in proportion, crushed, and passed through 80-mesh and 100-mesh sieves to obtain fine powder; water is added in a ratio of 2:1, and coarse pellets are made by a pellet making machine; and the Chinese medicine combination pills with a particle size of 4.0-4.5 mm are obtained through polishing and drying.
[0031] Example 2
[0032] Prescription: Scutellaria baicalensis 5g, Coptis chinensis 3.5g, Phellodendron chinense 2.5g, stir-fried Gardenia jasminoides 5.5g, Bupleurum chinense 4.5g, Forsythia suspensa 5.5g, and White Peony 3.5g.
[0033] The raw materials are taken in proportion, crushed, and made into capsules according to conventional preparation technology.
[0034] Example 3
[0035] Prescription: Scutellaria baicalensis 7g, Coptis chinensis 2.5g, Phellodendron chinense 3.5g, stir-fried Gardenia jasminoides 3g, Bupleurum chinense 7g, Forsythia suspensa 3g, White Peony Root 5g.
[0036] The raw materials are taken in proportion, crushed, and made into tablets according to conventional preparation technology.
[0037] Example 4
[0038] Prescription: Scutellaria baicalensis 7g, Coptis chinensis 3g, Phellodendron amurense 3g, stir-fried Gardenia jasminoides 4g, Bupleurum chinense 7g, Forsythia suspensa 4g, White Peony 4g.
[0039] The raw materials are taken in proportion, crushed, and made into powder according to conventional preparation technology.
[0040] Example 5
[0041] Prescription: Scutellaria baicalensis 8g, Coptis chinensis 4g, Phellodendron chinense 4g, stir-fried Gardenia jasminoides 4g, Bupleurum 8g, Forsythia suspensa 4g, White Peony 4g.
[0042] The raw materials are taken in proportion, boiled in water for extraction, and the decoction is made into oral liquid according to conventional preparation technology.
[0043] Example 6
[0044] Prescription: Scutellaria baicalensis 3.5g, Coptis chinensis 5.5g, Phellodendron chinense 1.5g, stir-fried Gardenia jasminoides 7.5g, Bupleurum chinense 3.5g, Forsythia suspensa 7.5g, and White Peony Root 2g.
[0045] The raw materials are taken in proportion, boiled in water for extraction, and the decoction is made into granules according to conventional preparation technology.
[0046] Example 7
[0047] Prescription: Scutellaria baicalensis 10g, Coptis chinensis 1.5g, Phellodendron chinense 5g, stir-fried Gardenia jasminoides 2g, Bupleurum chinense 10g, Forsythia suspensa 2g, White Peony ca. 7g.
[0048] The raw materials are taken in proportion, and 75% ethanol is added for reflux extraction, and the extract is made into capsules according to conventional preparation technology.
[0049] Example 8
[0050] Prescription: Scutellaria baicalensis 4g, Coptis chinensis 4.5g, Phellodendron amurense 2g, stir-fried Gardenia jasminoides 6.5g, Bupleurum chinense 4g, Forsythia suspensa 6.5g, White Peony 2.5g.
[0051] The raw materials are taken in proportion, and 75% ethanol is added for reflux extraction, and the extract is made into tablets according to conventional preparation technology.
[0052] Example 9
[0053] Prescription: Scutellaria baicalensis 9g, Coptis chinensis 2g, Phellodendron amurense 4.5g, stir-fried Gardenia jasminoides 2.5g, Bupleurum chinense 9g, Forsythia suspensa 2.5g, White Peony 6.5g.
[0054] The raw materials are taken in proportion, and 75% ethanol is added for reflux extraction, and the extract is made into pills according to conventional preparation technology.
[0055] Example 10
[0056] Prescription: 6g of Scutellaria baicalensis extract, 3g of Coptis chinensis extract, 3g of Phellodendron amurense extract, 4g of stir-fried Gardenia jasminoides extract, 6g of Bupleurum chinense extract, 4g of Forsythia suspensa extract, and 4g of White Peony Root extract.
[0057] Embodiment 11
[0058] Prescription: 5g of Scutellaria baicalensis extract, 3.5g of Coptis chinensis extract, 2.5g of Phellodendron chinense extract, 5.5g of stir-fried Gardenia jasminoides extract, 4.5g of Bupleurum chinense extract, 5.5g of Forsythia suspensa extract, and 3.5g of White Peony Root extract.
[0059] Example 12
[0060] Prescription: 7g of Scutellaria baicalensis extract, 2.5g of Coptis chinensis extract, 3.5g of Phellodendron chinense extract, 3g of stir-fried Gardenia jasminoides extract, 7g of Bupleurum chinense extract, 3g of Forsythia suspensa extract, and 5g of White Peony Root extract.
[0061] Embodiment 13
[0062] Prescription: 7g of Scutellaria baicalensis extract, 3g of Coptis chinensis extract, 3g of Phellodendron amurense extract, 4g of stir-fried Gardenia jasminoides extract, 7g of Bupleurum chinense extract, 4g of Forsythia suspensa extract, and 4g of White Peony Root extract.
[0063] Embodiment 14
[0064] Prescription: 8g of Scutellaria baicalensis extract, 4g of Coptis chinensis extract, 4g of Phellodendron amurense extract, 4g of Gardenia jasminoides extract, 8g of Bupleurum chinense extract, 4g of Forsythia suspensa extract, and 4g of White Peony Root extract.
[0065] Embodiment 15
[0066] Prescription: 3.5g of Scutellaria baicalensis extract, 5.5g of Coptis chinensis extract, 1.5g of Phellodendron chinense extract, 7.5g of stir-fried Gardenia jasminoides extract, 3.5g of Bupleurum chinense extract, 7.5g of Forsythia suspensa extract, and 2g of White Peony Root extract.
[0067] Example 16
[0068] Prescription: 10g of Scutellaria baicalensis extract, 1.5g of Coptis chinensis extract, 5g of Phellodendron amurense extract, 2g of stir-fried Gardenia jasminoides extract, 10g of Bupleurum chinense extract, 2g of Forsythia suspensa extract, and 7g of White Peony Root extract.
[0069] Embodiment 17
[0070] Prescription: 4g of Scutellaria baicalensis extract, 4.5g of Coptis chinensis extract, 2g of Phellodendron amurense extract, 6.5g of stir-fried Gardenia jasminoides extract, 4g of Bupleurum chinense extract, 6.5g of Forsythia suspensa extract, and 2.5g of White Peony Root extract.
[0071] Embodiment 18
[0072] Prescription: 9g of Scutellaria baicalensis extract, 2g of Coptis chinensis extract, 4.5g of Phellodendron chinense extract, 2.5g of stir-fried Gardenia jasminoides extract, 9g of Bupleurum chinense extract, 2.5g of Forsythia suspensa extract, and 6.5g of White Peony Root extract.
[0073] The extracts described in Examples 10-18 above are water extracts of the respective raw materials. The extracts are combined according to the formula amount and prepared into conventional oral dosage forms such as tablets, capsules, or granules according to conventional preparation processes.
[0074] Example 19 Effect of the Chinese medicine composition of the present invention on acute gouty arthritis model
[0075] 1 Experimental purpose: To establish an acute gouty arthritis mouse model by using the method of "sodium urate injection into the left ankle joint" (Experimental study on the effect of Danxi Gout Recipe on acute gouty arthritis in mice [J]. Journal of Traditional Chinese Medicine, 2015, 43(01): 59-62) and to observe the effects of various prescriptions on acute gouty arthritis in mice.
[0076] 2 Experimental Materials
[0077] 2.1 Experimental animals
[0078] 160 healthy KM mice, male, 18-20 g, SPF grade, purchased from Sibeifu (Beijing) Biotechnology Co., Ltd., license number: scxk (Beijing) 2019-0010.
[0079] 2.2 Test drugs
[0080] Prescription 1: 6g of Scutellaria baicalensis, 3g of Coptis chinensis, 3g of Phellodendron amurense, and 4g of stir-fried Gardenia jasminoides, mix according to proportion, grind, and pass through an 80-mesh sieve.
[0081] Prescription 2: 6g of Bupleurum, 4g of Forsythia, and 4g of White Peony Root, mix according to proportion, crush, and pass through an 80-mesh sieve.
[0082] Prescription three: 6g of Scutellaria baicalensis, 3g of Coptis chinensis, 3g of Phellodendron amurense, 4g of stir-fried Gardenia jasminoides, 6g of Bupleurum chinense, 4g of Forsythia suspensa, and 4g of White Peony Root. Mix them according to the proportion, grind them, and pass through an 80-mesh sieve.
[0083] Preparation method:
[0084] Weigh 16.25 mg of drug powder respectively, add purified water to 50 ml, mix well, and use them as prescription one, prescription two, and prescription three solutions.
[0085] The dosage of the drug was 6.5 mg crude drug / kg for each of the prescriptions 1, 2, and 3.
[0086] Positive drugs:
[0087] Benzbromarone tablets: German Hermann Pharmaceutical Factory, batch number: 2112357, specification: 50 mg;
[0088] Febuxostat tablets: Jiangsu Wanbang Biochemical Pharmaceutical Group Co., Ltd., batch number: 623117051, specification: 40 mg;
[0089] Tongfengshu tablets: Guizhou Kehui Pharmaceutical Co., Ltd., batch number: 230802, specification: each tablet weighs 0.35g;
[0090] Preparation method:
[0091] ① Take a benzbromarone tablet and dissolve it in water to make a 0.5mg / ml solution. The dosage volume is 20ml / kg body weight. The test dose for mice is 10mg / kg.
[0092] ② Take a Febuxostat tablet and dissolve it in water to make a 0.52mg / ml solution. The dosage volume is 20ml / kg body weight. The dose for mice is 10.4mg / kg.
[0093] ③Take one Tongfengshu tablet and dissolve it in water to make a 27.3mg / ml solution. The dosage volume is 20ml / kg body weight. The test dose for mice is 546mg / kg.
[0094] 2.3 Reagents
[0095] Sodium urate: Sigma, catalog number: U2875-100G
[0096] 3 Experimental methods
[0097] 3.1 Grouping, modeling and drug administration
[0098] 80 KM mice, male, 18-20g, were adaptively fed for three days and randomly divided into normal control group, model group, prescription group 1, prescription group 2, prescription group 3, Febuxostat group, benzbromarone tablet group, and Tongfengshu tablet group, with 10 mice in each group. Each group was pre-administered for 7 days, and 1 hour after the last administration, 30μl sodium urate suspension was injected into the left ankle joint cavity of the mice. The control group was injected with normal saline. 18 hours after modeling, blood was collected from the eyeballs, and the ankle joints of the mice were taken for pathological examination and ELISA detection of IL-6.
[0099] 80 KM mice, male, 18-20g, were adaptively fed for three days and randomly divided into normal control group, model group, prescription group 1, prescription group 2, prescription group 3, Febuxostat group, benzbromarone tablet group, and Tongfengshu tablet group, with 10 mice in each group. Each group was pre-administered for 7 days, and 1 hour after the last administration, 30μl sodium urate suspension was injected into the left ankle joint cavity of the mice. The control group was injected with normal saline. The diameter of the left ankle joint of the mice was measured before modeling and 6h, 12h, 24h, 48h, 72h, 96h, 120h, 144h, and 168h after modeling. The degree of swelling was calculated.
[0100] 3.2 Statistical processing methods
[0101] Data are presented as mean ± standard deviation It means that the data were tested using SPSS21.0 software, and the independent sample Mann-Whitney U test in non-parametric statistics was used for statistical processing, and P<0.05 was considered statistically significant.
[0102] 4 Experimental results
[0103] 4.1 Results of pathological examination of the ankle joint of mice
[0104] 4.1.1 Evaluation criteria
[0105] Table 1 Evaluation criteria
[0106]
[0107] Note: For evaluation criteria, see Peter Mann et al. International Standards for Terminology and Diagnostic Criteria for Pathological Changes in Rats and Mice (INHAND)[M]. Translated by Yang Lifeng, Zhou Xiangmei, and Zhao Deming. Beijing: China Agriculture Press, 2019.
[0108] 4.1.2 Pathological test results
[0109] The results are shown in Table 2. Figure 1 . HE staining observation seven days after modeling showed that the ankle joints of mice in the control group had smooth and flat cartilage surfaces, uniform distribution and neat arrangement of chondrocytes, clear layers, normal synovial structure, no hyperplasia and inflammatory cell infiltration, and no secretions in the joint cavity. The joint surface structure of mice in the model group was intact, the cartilage surface was smooth and flat, chondrocytes were uniformly distributed and neatly arranged, synovial hyperplasia, synovial blood vessel hyperplasia accompanied by inflammatory cell infiltration, and a large amount of fibroinflammatory exudate was visible in the joint cavity; compared with the model group, the pathological damage of the joints of mice in the prescription 1, prescription 2, prescription 3, Febuxostat group and Tongfengshu tablet group was alleviated to varying degrees, and the pathological scores of the prescription 3 and Tongfengshu tablet groups were significantly reduced (P<0.05).
[0110] Table 2 Ankle joint pathological scores of mice in each group
[0111]
[0112]
[0113] *Compared with the model group, P<0.05; △ Compared with the control group, P<0.05.
[0114] 4.2 IL-6 test results
[0115] The results are shown in Table 3. Compared with the control group, the IL-6 level in the serum of the mice in the model group was significantly increased (P<0.05); compared with the model group, the IL-6 level in the serum of the mice in the prescription group 3, the Febuxostat tablets group, the Benzbromarone tablets group, and the Tongfengshu tablets group was significantly decreased (P<0.05).
[0116] Table 3 Results of serum IL-6 levels in mice in each group ( n=10)
[0117]
[0118] *Compared with the model group, P<0.05; △ Compared with the control group, P<0.05.
[0119] 4.3. Results of swelling of the left ankle joint of mice
[0120] The results are shown in Tables 4-1 and 4-2. The swelling of the left ankle joint of mice injected with sodium urate in the model group was significantly increased compared with the control group, and there were significant differences in the administration of 6h, 12h, 24h, 48h, 72h, 96h, and 120h compared with the control group (P<0.05); compared with the model group, the swelling of prescription one was significantly reduced at 48h, 72h, 96h, and 120h (P<0.05); the swelling of prescription two was significantly reduced at 12h, 48h, 72h, 96h, and 120h (P<0.05); the swelling of prescription three was significantly reduced at 6h, 1 The swelling degree was significantly reduced at 2h, 24h, 48h, 72h, 96h and 120h (P<0.05); the swelling degree was significantly reduced at 6h, 12h, 24h, 48h, 72h, 96h and 120h in the Febuxostat tablets group (P<0.05); the swelling degree was significantly reduced at 12h, 48h, 72h, 96h and 120h in the benzbromarone tablets group (P<0.05); the swelling degree was significantly reduced at 12h, 72h, 96h and 120h in the Tongfengshu tablets group (P<0.05).
[0121] Table 4-1 Results of swelling of the left ankle joint of mice at different time points ( n=10)
[0122]
[0123] Table 4-2 Results of swelling of the left ankle joint of mice at different time points ( n=10)
[0124]
[0125] The above experimental results show that the Chinese medicine composition of the present invention can reduce joint pathological damage and relieve joint swelling in mice with gouty arthritis.
[0126] Example 20 Effect of the Chinese medicine composition of the present invention on hyperuricemia animal model
[0127] 1 Experimental Purpose
[0128] A hyperuricemia mouse model was established by the method of “intraperitoneal injection of potassium oxonate” (Study on the intervention effect of lyophilized powder of Phyllanthus emblica on hyperuricemia and gout animal models [D]. Dali University, 2024), and the effect of the drug on the hyperuricemia mouse model was observed to determine its effect in lowering uric acid.
[0129] 2 Experimental Materials
[0130] 2.1 Experimental animals
[0131] 80 healthy KM mice, male, 18-20 g, SPF grade, purchased from Sibeifu (Beijing) Biotechnology Co., Ltd., license number: scxk (Beijing) 2019-0010.
[0132] 2.2 Test drugs
[0133] Prescription 1: Mix 6g of Scutellaria baicalensis, 3g of Coptis chinensis, 3g of Phellodendron amurense, and 4g of stir-fried Gardenia jasminoides in proportion, grind them, and pass through an 80-mesh sieve.
[0134] Prescription 2: Mix 6g of Bupleurum, 4g of Forsythia, and 4g of White Peony Root in proportion, grind them, and pass through an 80-mesh sieve.
[0135] Prescription three: Mix 6g of Scutellaria baicalensis, 3g of Coptis chinensis, 3g of Phellodendron amurense, 4g of stir-fried Gardenia jasminoides, 6g of Bupleurum chinense, 4g of Forsythia suspensa, and 4g of White Peony Root in proportion, grind them, and pass through an 80-mesh sieve.
[0136] Preparation method:
[0137] Weigh 16.25 mg of drug powder respectively, add purified water to 50 ml, mix well, and use them as prescription one, prescription two, and prescription three solutions.
[0138] The dosage of the drug was 6.5 mg crude drug / kg for each of the prescriptions 1, 2, and 3.
[0139] Positive drugs:
[0140] Benzbromarone tablets: German Hermann Pharmaceutical Factory, batch number: 2112357, specification: 50 mg;
[0141] Febuxostat tablets: Jiangsu Wanbang Biochemical Pharmaceutical Group Co., Ltd., batch number: 623117051, specification: 40 mg;
[0142] Tongfengshu tablets: Guizhou Kehui Pharmaceutical Co., Ltd., batch number: 230802, specification: each tablet weighs 0.35g.
[0143] Preparation method:
[0144] ① Take a benzbromarone tablet and dissolve it in water to make a 0.5mg / ml solution. The dosage volume is 20ml / kg body weight. The test dose for mice is 10mg / kg.
[0145] ② Take a Febuxostat tablet and dissolve it in water to make a 0.52mg / ml solution. The dosage volume is 20ml / kg body weight. The dose for mice is 10.4mg / kg.
[0146] ③Take one Tongfengshu tablet and dissolve it in water to make a 27.3mg / ml solution. The dosage volume is 20ml / kg body weight. The test dose for mice is 546mg / kg.
[0147] 2.3 Reagents
[0148] Potassium oxonate: Shanghai MacLean Biochemical Technology Co., Ltd., batch number: C14819603.
[0149] 3 Experimental methods
[0150] 3.1 Grouping, modeling and drug administration
[0151] 80 male KM mice were adaptively fed for 3 days and randomly divided into normal control group, model group, prescription group 1, prescription group 2, prescription group 3, Febuxostat tablets group, benzbromarone tablets group, and Tongfengshu tablets group, with 10 mice in each group. The corresponding drugs were gavaged every day, and the normal group and model group were gavaged with equal volumes of pure water for 7 consecutive days. Except for the normal group, the rest of the animals were injected with 300 mg / kg of potassium oxonate intraperitoneally 1 hour after administration for modeling. Blood was collected 1 hour after the last modeling, and the supernatant was centrifuged. Detection indicators: UA (uric acid) and Cr (creatinine) levels in serum.
[0152] 3.2 Statistical processing methods
[0153] Data are presented as mean ± standard deviation It means that the data were tested using SPSS21.0 software, and the independent sample Mann-Whitney U test in non-parametric statistics was used for statistical processing, and P<0.05 was considered statistically significant.
[0154] 4 Experimental results
[0155] The results are shown in Table 5. Compared with the control group, the levels of UA and Cr in the serum of mice in the model group were significantly increased (P<0.05), indicating that the model was successfully established. Compared with the model group, the levels of UA and Cr in the serum of mice in the prescription group 3, the Febuxostat tablets group, the Benzbromarone tablets group, and the Tongfengshu tablets group were significantly decreased (P<0.05).
[0156] Table 5 Results of serum UA and Cr levels in each group of mice ( n=10)
[0157]
[0158]
[0159] *Compared with the model group, P<0.05; △ Compared with the control group, P<0.05.
[0160] The above experimental results show that the Chinese medicine composition of the present invention has a certain effect of lowering uric acid.
[0161] Example 21 Analgesic experiment of the Chinese medicine composition of the present invention
[0162] (I) Effects on the analgesic effect of acetic acid writhing animal model
[0163] 1 Experimental purpose: To establish a mouse pain model by intraperitoneal injection of 0.6% glacial acetic acid, observe the effect of the drug on the mouse pain model, and determine its analgesic effect.
[0164] 2 Experimental Materials
[0165] 2.1 Experimental animals
[0166] 90 healthy KM mice, 18-20 g, SPF grade, were purchased from Beijing Huafukang Biotechnology Co., Ltd., license number: scxk (Beijing) 2019-0008.
[0167] 2.2 Test drugs
[0168] Experimental drugs: 6g of Scutellaria baicalensis, 3g of Coptis chinensis, 3g of Phellodendron amurense, 4g of stir-fried Gardenia jasminoides, 6g of Bupleurum chinense, 4g of Forsythia suspensa, and 4g of White Peony Root were mixed in proportion, crushed, and passed through an 80-mesh sieve.
[0169] Preparation method:
[0170] Weigh 55.25 mg of drug powder, add purified water to 85 ml, mix well, and use as high-dose solution;
[0171] Take 35 ml of the high-dose solution, add purified water to 70 ml, mix well, and use it as the medium-dose solution;
[0172] Take 20ml of the medium-dose solution and add purified water to 40ml. Mix well to prepare the low-dose solution.
[0173] The drug was administered orally at 20 ml / kg body weight. The high, medium and low dose groups were administered with 13 mg crude drug / kg, 6.5 mg crude drug / kg and 3.25 mg crude drug / kg, respectively.
[0174] Positive drugs:
[0175] Ibuprofen sustained-release capsules: Jilin Lisheng Pharmaceutical Co., Ltd., specification: 0.3g, batch number: 20200913. The clinical daily dose is 0.6g.
[0176] Preparation method:
[0177] Take 1 capsule and dissolve it in water to make a 0.05mg / ml solution. The dosage volume is 0.2ml / 10g body weight. The dose for mice is 1mg / kg.
[0178] 2.3 Reagents
[0179] Glacial acetic acid: analytical grade, Beijing Chemical Plant, batch number: 190507.
[0180] 3 Experimental methods
[0181] 3.1 Grouping, modeling and drug administration
[0182] 66 KM mice were randomly divided into 6 groups, including normal control group, model group, high, medium and low dose groups of experimental drugs, and positive drug group, with 11 mice in each group. The animals in each drug group were given corresponding drugs by gavage, and the control group was given an equal volume of purified water by gavage. The drug was given once a day for 7 consecutive days. One hour after the last drug administration, the animals in each group were intraperitoneally injected with 0.6% glacial acetic acid, and the number and latency of writhing reactions (twisting reactions with trunk and hind limb extension) within 15 minutes of injection were recorded.
[0183] Analgesia rate = (number of writhing reactions in the control group - number of writhing reactions in the drug-treated group) / number of writhing reactions in the control group × 100%.
[0184] 3.2 Statistical processing methods
[0185] Data are presented as mean ± standard deviation It means that the data were tested using SPSS21.0 software, and the independent sample Mann-Whitney U test in non-parametric statistics was used for statistical processing, and P<0.05 was considered statistically significant.
[0186] 4 Experimental results
[0187] The results are shown in Table 6. Compared with the model group, the writhing latency of mice in the experimental drug medium, low dose groups and positive drug groups was significantly increased (P<0.05); the writhing times of mice in the experimental drug high, medium, low dose groups and positive drug groups were significantly reduced (P<0.05).
[0188] Table 6 Effect of acetic acid on the number of writhing times in mice ( n=11)
[0189]
[0190]
[0191] *Compared with the model group, P<0.05.
[0192] (II) Hot plate pain threshold test
[0193] 1 Experimental Materials
[0194] 1.1 Experimental animals
[0195] 80 healthy KM mice, 18-20 g, SPF grade, were purchased from Sibeifu (Beijing) Biotechnology Co., Ltd., license number: scxk (Beijing) 2019-0010.
[0196] 1.2 Test drugs
[0197] Experimental drugs: 6g of Scutellaria baicalensis, 3g of Coptis chinensis, 3g of Phellodendron amurense, 4g of stir-fried Gardenia jasminoides, 6g of Bupleurum chinense, 4g of Forsythia suspensa, and 4g of White Peony Root were mixed in proportion, crushed, and passed through an 80-mesh sieve.
[0198] Preparation method:
[0199] Weigh 55.25 mg of drug powder, add purified water to 85 ml, mix well, and use as high-dose solution;
[0200] Take 35 ml of the high-dose solution, add purified water to 70 ml, mix well, and use it as the medium-dose solution;
[0201] Take 20 ml of the medium-dose solution, add purified water to 40 ml, mix well, and use as the low-dose solution.
[0202] The drug was administered orally at 20 ml / kg body weight. The high, medium and low dose groups were administered with 13 mg crude drug / kg, 6.5 mg crude drug / kg and 3.25 mg crude drug / kg, respectively.
[0203] Positive drug: Ibuprofen sustained-release capsules, Jilin Lisheng Pharmaceutical Co., Ltd., specification: 0.3g, batch number: 20200913, clinical daily dose is 0.6g.
[0204] 2 Experimental methods
[0205] 2.1 Grouping, modeling and drug administration
[0206] 60 KM mice were randomly divided into 6 groups: normal control group, model group, high, medium and low dose groups of experimental drugs, and positive drug group, with 10 mice in each group. The animals in each drug group were gavaged with the corresponding drugs, and the control group was gavaged with an equal volume of pure water. The drugs were administered once a day for 7 consecutive days. One hour after the last administration, the pain threshold time of mice in each group was measured.
[0207] 2.2 Statistical processing methods
[0208] Data are presented as mean ± standard deviation It means that the data were tested using SPSS21.0 software, and the independent sample Mann-Whitney U test in non-parametric statistics was used for statistical processing, and P<0.05 was considered statistically significant.
[0209] 3 Experimental results
[0210] The results are shown in Table 7. Compared with the model group, the pain threshold of mice in the high-dose and medium-dose groups and the positive drug group of the experimental drug was significantly increased (P<0.05).
[0211] Table 7 Effects of the hot plate pain threshold on mice ( n=10)
[0212] Grouping Pain threshold (S) Model Group 7.99±1.43 High dose group 13.77±3.24* Medium dose group 11.34±3.36* Low dose group 8.29±1.69 Positive drug group 11.06±2.33*
[0213] *Compared with the model group, P<0.05.
[0214] The above experimental results show that the Chinese medicine composition of the present invention has a significant analgesic effect.
[0215] The above description is only a preferred embodiment of the present invention and does not limit the present invention in any form. Any simple modification, equivalent changes and modifications made to the above embodiments based on the technical essence of the present invention are still within the protection scope of the technical solution of the present invention.
Claims
1. A Chinese medicine composition for treating hyperuricemia and gout, characterized in that: The drug is prepared from the following raw materials in parts by weight: 3-12 parts by weight of scutellaria baicalensis, 1.5-6 parts by weight of coptis chinensis, 1.5-6 parts by weight of phellodendron amurense, 2-8 parts by weight of gardenia jasminoides, 3-12 parts by weight of bupleurum chinense, 2-8 parts by weight of forsythia suspensa, and 2-8 parts by weight of white peony root.
2. The Chinese medicine composition for treating hyperuricemia and gout according to claim 1, characterized in that: The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 4-8 parts by weight of scutellaria baicalensis, 2-4 parts by weight of coptis chinensis, 2-4 parts by weight of phellodendron amurense, 3-6 parts by weight of gardenia jasminoides, 4-8 parts by weight of bupleurum, 3-6 parts by weight of forsythia suspensa, and 3-6 parts by weight of white peony root.
3. The Chinese medicine composition for treating hyperuricemia and gout according to claim 2, characterized in that: The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 6 parts by weight of scutellaria baicalensis, 3 parts by weight of coptis chinensis, 3 parts by weight of phellodendron amurense, 4 parts by weight of gardenia jasmine, 6 parts by weight of bupleurum, 4 parts by weight of forsythia suspensa, and 4 parts by weight of white peony root.
4. The Chinese medicine composition for treating hyperuricemia and gout according to claim 2, characterized in that: The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 5 parts by weight of scutellaria baicalensis, 3.5 parts by weight of coptis chinensis, 2.5 parts by weight of phellodendron amurense, 5.5 parts by weight of gardenia jasminoides, 4.5 parts by weight of bupleurum chinense, 5.5 parts by weight of forsythia suspensa, and 3.5 parts by weight of white peony root.
5. The Chinese medicine composition for treating hyperuricemia and gout according to claim 2, characterized in that: 7 parts by weight of Scutellaria baicalensis, 2.5 parts by weight of Coptidis chinensis, 3.5 parts by weight of Phellodendron chinense, 3 parts by weight of Gardenia jasminoides, 7 parts by weight of Bupleurum chinense, 3 parts by weight of Forsythia suspensa, and 5 parts by weight of White Peony Root.
6. The Chinese medicine composition for treating hyperuricemia and gout according to any one of claims 1 to 5, characterized in that: The gardenia is fried gardenia.
7. The method for preparing the Chinese medicine composition for treating hyperuricemia and gout according to claim 1, characterized in that: The Chinese medicine composition is prepared by mixing the raw materials after crushing, or is an extract obtained by mixing or extracting the raw materials separately, or is an effective part obtained by further refining and purifying the extract, or is a conventional dosage form prepared by adding pharmaceutically acceptable excipients to the extract / effective part.
8. The method for preparing the Chinese medicine composition for treating hyperuricemia and gout according to claim 7, characterized in that: The extraction includes: decoction extraction, reflux extraction, immersion extraction, ultrasonic extraction, percolation extraction, microwave extraction; the purification includes: water extraction and alcohol precipitation, alkali dissolution and acid precipitation, various column chromatography purification methods; the conventional dosage forms include: capsules, tablets, granules, gels, sustained-release agents, oral liquids, pills or nanoformulations; the pharmaceutically acceptable excipients include: fillers, disintegrants, lubricants, suspending agents, adhesives, sweeteners, flavoring agents, preservatives, and bases; the fillers include: starch, pregelatinized starch, lactose, Mannitol, chitin, microcrystalline cellulose, sucrose; the disintegrant includes starch, pregelatinized starch, microcrystalline cellulose, sodium carboxymethyl starch, cross-linked polyvinyl pyrrolidone, low-substituted hydroxypropyl cellulose, cross-linked sodium carboxymethyl cellulose; the lubricant includes magnesium stearate, sodium lauryl sulfate, talc, silicon dioxide; the suspending agent includes polyvinyl pyrrolidone, microcrystalline cellulose, sucrose, agar, hydroxypropyl methylcellulose; the binder includes starch slurry, polyvinyl pyrrolidone, hydroxypropyl methylcellulose.
9. The method for preparing the Chinese medicine composition for treating hyperuricemia and gout according to claim 8, characterized in that: The extract is a water extract of each raw material drug, or an organic solvent extract, or a refined product obtained by further refining and purifying the water extract / organic solvent extract; the organic solvent is selected from one or more of methanol, 20-95% ethanol solution, and acetone.
10. Use of the traditional Chinese medicine composition for treating hyperuricemia and gout according to claim 1 in the preparation of a medicament for treating hyperuricemia and / or gout.
Citation Information
Patent Citations
Traditional Chinese medicine composition for treating gout
CN103933224A
Heat clearing and detoxicating Chinese medicinal formula
CN106539950A
Feed additive for wintersweet leaf intoxication of goat
CN106728229A
Completely-new formula of heat clearing and detoxifying traditional Chinese medicine
CN108452065A
Traditional Chinese medicine composition for reducing uric acid and / or resisting inflammation and relieving pain and application thereof
CN116350728A
